<SEC-DOCUMENT>0001104659-24-086088.txt : 20240806
<SEC-HEADER>0001104659-24-086088.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806070841
ACCESSION NUMBER:		0001104659-24-086088
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		241177061

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2419327d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ptgx="http://protagonist-inc.com/20240806">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ptgx_protagonist%2Dinc.com_20240806 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240806_20240806 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001377121 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000004" name="dei:EntityCentralIndexKey">0001377121</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgx-20240806.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-06</xbrli:startDate>
        <xbrli:endDate>2024-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0; text-indent: 1.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20240806__20240806_zhX6Wt0kVip9"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>CURRENT REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Pursuant to Section
13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>of the Securities
Exchange Act of 1934</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <b><span id="xdx_90E_edei--DocumentPeriodEndDate_c20240806__20240806_zd8wMoS3c8Sd"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 6, 2024</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20240806__20240806_zdgyMEx5aUq3"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000011" name="dei:EntityRegistrantName">PROTAGONIST THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20240806__20240806_zMxSqs9p6wg5"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityFileNumber_c20240806__20240806_zKfQHVRq5byf"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000013" name="dei:EntityFileNumber">001-37852</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240806__20240806_zHdBSspNAUwk"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-0505495</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br/>
File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/>
Identification No.)</span></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protagonist Therapeutics,&#160;Inc.</b><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20240806__20240806_zCgONkq9aJwi"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000015" name="dei:EntityAddressAddressLine1">7707 Gateway Blvd.</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20240806__20240806_zlcPbuMIl62d"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 140</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20240806__20240806_zo6opoD2jnJ"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000017" name="dei:EntityAddressCityOrTown">Newark</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20240806__20240806_zfY0q4Vrh2l4"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20240806__20240806_zbJrRgOvt1kc"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000019" name="dei:EntityAddressPostalZipCode">94560-1160</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90F_edei--CityAreaCode_c20240806__20240806_zbt64FfZ0Xj6"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000020" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20240806__20240806_zNqCDsJbM9g6"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000021" name="dei:LocalPhoneNumber">474-0170</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20240806__20240806_zbcbJ84Zyq4i"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20240806__20240806_zik4qILhcchi"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20240806__20240806_zVaDi7S9qUI5"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20240806__20240806_zXoFMKVQBMni"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 35%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 35%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which<br/>
registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--Security12bTitle_c20240806__20240806_zA8ApVZVhJRh"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.00001</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--TradingSymbol_c20240806__20240806_zpQSzGM9lqw5"><ix:nonNumeric contextRef="AsOf2024-08-06" id="Fact000027" name="dei:TradingSymbol">PTGX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--SecurityExchangeName_c20240806__20240806_zhx3hBIE7Ssk"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Emerging growth company </span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240806__20240806_zldtJMEiIu7d"><ix:nonNumeric contextRef="AsOf2024-08-06" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>Item 2.02. Results of Operations
and Financial Condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">On August&#160;6, 2024, Protagonist
Therapeutics,&#160;Inc. reported its financial results for the second quarter ended June&#160;30, 2024. A copy of the press release titled
&#8220;Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update&#8221; is furnished pursuant to Item 2.02
as Exhibit&#160;99.1 hereto and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 </b></span>&#160;<b>Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 88%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2419327d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2419327d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated
    August&#160;6, 2024, titled &#8220;Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate
    Update.&#8221;</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this report, including the exhibit hereto, shall
not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of Section&#160;11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended. The information contained herein
and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by Protagonist Therapeutics,&#160;Inc., whether made before or after the date hereof, regardless of any general incorporation language
in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Protagonist
    Therapeutics,&#160;Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August&#160;6, 2024</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td rowspan="2" style="width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Asif Ali</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asif Ali</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5LpoGFeynRUWsIkXE32BXCbbZsonaHslbGlvEZWFZZt6MELFY08pUyHBeFDkcsW4q7REKvCKjvWBwZJttCuEWeDPOs7a+f39gRoHBwExHSukg9NancVimIKdjORurCch5Kudw2Inoq2dkr6ZE642uQNsSDkwNG/SauyHhqFuyVHd91QnZGbIpJCM5yG9QMlGwp6d+Ed8d5HkmorifSKyZHk1wLVuP9kvCssI61LmB/m/0AQuDSpU= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2419327d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2419327d1_ex99-1img001.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Protagonist Reports
Second Quarter 2024 Financial Results and Provides Corporate Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>JNJ-2113 Phase
3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint
portion of the studies in Q4 2024</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>JNJ-2113 Phase
2b ANTHEM clinical trial in moderate-to-severe ulcerative colitis expected to complete the primary endpoint portion of the study in Q4
2024</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Rusfertide Phase
2 REVIVE study long-term follow-up data in polycythemia vera presented at <FONT STYLE="background-color: white">European Hematology Association
(EHA) 2024; study </FONT>showed durable hematocrit control, decreased phlebotomy use, long-term tolerability and no new safety signals</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Rusfertide topline
results from the 32-week primary endpoint of the Phase 3 VERIFY study expected in Q1 2025</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Cash, cash equivalents
and marketable securities of $595.4M as of June&nbsp;30, 2024, anticipated to provide cash runway through end of 2027</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>NEWARK,
Calif.,&nbsp;August&nbsp;6, 2024&nbsp;&ndash;&nbsp;</B>Protagonist Therapeutics&nbsp;(Nasdaq: PTGX) (&ldquo;Protagonist&rdquo; or &ldquo;the
Company&rdquo;) today reported financial results for the second quarter ended June&nbsp;30, 2024, and provided a corporate update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;During the second quarter of
2024 our team made tremendous strides in the late-stage clinical development of rusfertide and also in leveraging our proprietary discovery
platform for early-stage, but highly differentiated, oral peptides-based discovery programs,&rdquo; said Dinesh V. Patel, Ph.D., the
Company&rsquo;s President and CEO. &ldquo;We presented updated long-term data from the REVIVE Phase 2 trial at EHA that reaffirms rusfertide&rsquo;s
durability of positive response in polycythemia vera, and we look forward to the Phase 3 VERIFY 32-week primary endpoint readout in Q1
2025. We are excited at the prospect of introducing multiple new development candidates in a variety of indications over the next 12
months where oral peptides would offer a strong differentiation versus existing options. Additionally, our addition to the S&amp;P SmallCap
600<SUP>&reg;</SUP> index highlights the value Protagonist brings to shareholders and provides additional visibility within the investment
community.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dr.&nbsp;Patel continued, &ldquo;We
are also very pleased with the rapid pace of enrollment in the five different ongoing Phase 3 trials of JNJ-2113 in psoriasis and the
Phase 2b study in ulcerative colitis<FONT STYLE="font-family: Times New Roman, Times, Serif">. With the primary endpoint portion of the
ICONIC-LEAD in moderate-to-severe plaque psoriasis,&nbsp;ICONIC-TOTAL in psoriasis in special body regions, and ANTHEM in ulcerative
colitis studies all expected to be completed this year, we look forward to uncovering the potential and differentiation of JNJ-2113,
the first and only targeted oral IL-23 receptor antagonist (IL23Ri) peptide.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: #212529"><FONT STYLE="font-size: 10pt; background-color: white"><B>Second
Quarter 2024 Recent Developments and Upcoming Milestones</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; background-color: white">Dr.&nbsp;Newman
                                            Yeilding joined the Protagonist executive team as Chief Scientific Advisor, effective August&nbsp;1<SUP>st</SUP>.
                                            His 20-plus years of work experience, including seven years as the Head of Immunology at
                                            Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, </FONT><FONT STYLE="font-size: 10pt">covered
                                            a broad range of research and development (R&amp;D) responsibilities in the inflammation
                                            and immunomodulatory (I&amp;I) diseases space including Rheumatology, Gastroenterology, Dermatology
                                            and Pediatric Development. Dr.&nbsp;Yeilding&rsquo;s insights in the field and guidance on
                                            the expansion of the Company&rsquo;s discovery platform and R&amp;D pipeline will be of significant
                                            value.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B><I>Rusfertide:
Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Updated
                                            long-term (up to 3-year) follow-up data from the REVIVE Phase 2 study in PV was presented
                                            at the <FONT STYLE="background-color: white">EHA 2024 Congress. The presentation</FONT> showed
                                            durability of response as measured by hematocrit (Hct) control (&lt; 45%), decreased phlebotomy
                                            use, long-term tolerability, and no new safety signals.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; background-color: white">The
                                            Company expects to announce top-line data for the </FONT><FONT STYLE="font-size: 10pt">VERIFY
                                            <FONT STYLE="background-color: white">study&rsquo;s 32-week primary efficacy endpoint in
                                            PV in Q1 of 2025.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white; color: #212529"><FONT STYLE="font-size: 10pt"><B><I>JNJ-2113:
Oral IL-23 Receptor Antagonist for Psoriasis (PsO) and Ulcerative Colitis (UC)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #FEFEFE">On
                                            July&nbsp;30, 2024, data summarizing preclinical findings and its translational correlation
                                            with phase 1 clinical data on JNJ-2113 were published in the&nbsp;journal <I>Scientific Reports</I>,
                                            a <I>Nature </I>publication<I>&nbsp;</I>and the fifth most-cited journal in the world</FONT><FONT STYLE="font-size: 10pt; background-color: #FEFEFE">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            16-week primary endpoint portion of the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies in PsO<SUP>1</SUP>,
                                            which began in Q4 of 2023, are expected to be completed in Q4 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            12-week primary endpoint portion of the</FONT> <FONT STYLE="font-size: 10pt; background-color: white">Phase
                                            2b ANTHEM multicenter, randomized, placebo-controlled, dose-ranging study of JNJ-2113 for
                                            the treatment of moderately-to-severely active UC<SUP>2 </SUP></FONT><FONT STYLE="font-size: 10pt">is
                                            expected to <FONT STYLE="font-family: Times New Roman, Times, Serif">be completed in Q4 2024.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            16-week primary endpoint portion of the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 superiority
                                            studies in PsO<SUP>3</SUP>, evaluating the safety and efficacy of JNJ-2113 compared with
                                            both placebo and deucravacitinib is expected to be completed in Q1 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            primary endpoint portion of the Phase 3 in pustular and erythrodermic psoriasis<SUP>4</SUP>
                                            evaluating the safety and efficacy of JNJ-2113 in approximately 16 subjects compared with
                                            placebo is expected to be completed in Q1 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><FONT STYLE="font-size: 10pt"><B><I>Discovery
Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagonist
                                            is pursuing the discovery of novel oral peptides against various clinically validated biological
                                            targets in hematology,&nbsp;I&amp;I diseases, and obesity and related indications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company announced an oral IL-17 discovery program in January&nbsp;2024 with a development
                                            candidate expected to be announced by end of 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagonist
                                            is also anticipating the nomination of a development candidate in the hematology space and
                                            an oral peptide-based development candidate in the obesity program by the middle of 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>1
</SUP>ICONIC-LEAD (NCT06095115) and ICONIC-TOTAL (NCT06095102)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2
</SUP>ANTHEM (NCT06049017)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>3
</SUP>ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>4
</SUP>Pustular/Erythrodermic (NCT06295692)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Second Quarter 2024 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash,
                                            Cash Equivalents and Marketable Securities</B>: Cash, cash equivalents and marketable securities
                                            as of June&nbsp;30, 2024, were $595.4 million as compared to $341.6 million as of December&nbsp;31,
                                            2023. The increase reflects the receipt in April&nbsp;2024 of the upfront payment from the
                                            </FONT><FONT STYLE="font-size: 10pt">Takeda Worldwide License and Collaboration Agreement
                                            for rusfertide (the &ldquo;Collaboration Agreement&rdquo;) entered in Q1 2024<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">(in thousands, except per share amounts)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; text-indent: 0in">License and collaboration revenue</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,167</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">259,120</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Research and development expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33,520</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33,182</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">67,254</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">60,598</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">General and administrative expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,440</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,172</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">17,777</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Net income (loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(30,616</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(38,460</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">176,724</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(72,185</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-indent: 10pt">Basic earnings (loss) per share</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(0.50</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(0.68</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">2.89</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(1.34</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-style: italic; text-indent: 10pt">Diluted earnings (loss) per share</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(0.50</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(0.68</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">2.77</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: right">(1.34</TD><TD STYLE="font-size: 10pt; font-style: italic; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>License
                                            and Collaboration Revenue</B>: The Collaboration Agreement included a <FONT STYLE="font-family: Times New Roman, Times, Serif">nonrefundable
                                            </FONT>upfront payment of $300.0 million of which we recognized $255.0 million during the
                                            first quarter of 2024.&nbsp;The remaining $45.0 million was recorded as deferred revenue
                                            to be recognized over time as the Company satisfies its performance obligation to complete
                                            the ongoing Phase 3 VERIFY trial for rusfertide.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">During the second quarter
of 2024, we recognized $4.2 million of this deferred revenue balance as revenue based on costs incurred in the quarter compared to the
total budget for this performance obligation. License and collaboration revenue of $259.1 million for the six months ended June&nbsp;30,
2024, is comprised of: (i)&nbsp;$255.0 million of the $300.0 million upfront cash payment for the Takeda Collaboration Agreement recorded
in the first quarter of 2024 and (ii)&nbsp;the $4.2 million recorded as revenue during the second quarter of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Research
                                            and Development (&quot;R&amp;D&quot;) Expenses</B>: The increase of $6.7 million in R&amp;D
                                            expenses for the six months ended June&nbsp;30, 2024 from the prior year period was primarily
                                            due to increases in drug discovery and pre-clinical research expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>General
                                            and Administrative (&quot;G&amp;A&quot;) Expenses</B>: The increase in G&amp;A expenses for
                                            the six months ended June&nbsp;30, 2024 of $6.6 million from the prior year period was primarily
                                            due to $4.6 million in one-time advisory and legal fees related to the Takeda collaboration
                                            and an increase of approximately $2.0 million in stock-based compensation and other personnel-related
                                            expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Net
                                            Income (Loss)</B>: Net loss was ($30.6) million, or ($0.50) per basic and diluted share,
                                            for the three months ended June&nbsp;30, 3024, as compared to a net loss of ($38.5) million,
                                            or ($0.68) per basic and diluted share, for the three months ended June&nbsp;30, 2023. Net
                                            income was $176.7 million, or $2.89 per basic share and $2.77 per diluted share, for the
                                            six months ended June&nbsp;30, 2024, as compared to a net loss of ($72.2) million, or ($1.34)
                                            per basic and diluted share, for the six months ended June&nbsp;30, 2023.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About Protagonist</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; background-color: white">Protagonist
Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235)
in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and
Johnson&nbsp;&amp; Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist
collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further
clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis.
Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development
program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were
published in <I>The New England Journal of Medicine </I>in February&nbsp;2024. The open-label extension (OLE) component of REVIVE has
also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in
the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda
pursuant to a worldwide collaboration and license agreement with Takeda announced in January&nbsp;2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; background-color: white">More
information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at&nbsp;<B><U>www.protagonist-inc.com</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: #212529"><FONT STYLE="font-size: 10pt"><B>Cautionary
Note on Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">This
press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements regarding the potential benefits of JNJ-2113 and rusfertide, the timing of
JNJ-2113 and rusfertide clinical trials, and timing of developments in our discovery programs. In some cases, you can identify these
statements by forward-looking words such as &quot;anticipate,&quot; &quot;believe,&quot; &quot;may,&quot; &quot;will,&quot; &quot;expect,&quot;
or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including,
but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our
collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and
compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual
property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can
be found in our periodic filings with the Securities and Exchange Commission, including under the heading &quot;Risk Factors&quot; contained
in our most recently filed periodic reports on Form&nbsp;10-K and Form&nbsp;10-Q filed with the Securities and Exchange Commission. Forward-looking
statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release.
Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation
to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this
press release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><FONT STYLE="font-size: 10pt">Corey
Davis, Ph.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">LifeSci Advisors<BR>
<U>cdavis@lifesciadvisors.com</U><BR>
+1 212 915 2577</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Media Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><FONT STYLE="font-size: 10pt">Virginia Amann<BR>
ENTENTE Network of Companies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><FONT STYLE="font-size: 10pt">virginiaamann@ententeinc.com<BR>
+1 833 500 0061</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>PROTAGONIST THERAPEUTICS,
INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Condensed Consolidated Statements
of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(Amounts in thousands except
share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; text-indent: 0in">License and collaboration revenue</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,167</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">259,120</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 10pt"><FONT STYLE="font-size: 10pt">Research and development <SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,520</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,182</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,254</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,598</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 10pt"><FONT STYLE="font-size: 10pt">General and administrative <SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,440</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,172</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,777</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 20pt">Total operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,960</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,354</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">91,604</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">78,375</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Income (loss) from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(38,793</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(42,354</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">167,516</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(78,375</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,404</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,780</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,404</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Other income (expense), net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">97</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">78</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(214</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Income (loss) before income tax benefit (expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(31,292</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(38,460</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">179,374</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(72,185</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Income tax benefit (expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">676</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,650</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Net income (loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(30,616</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(38,460</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">176,724</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(72,185</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Net income (loss) per share, basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.50</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.68</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.34</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Net income (loss) per share, diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.50</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.68</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.77</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.34</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Weighted-average shares used to compute net income (loss) per share, basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">61,305,289</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">56,775,742</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">61,080,489</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">53,691,965</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Weighted-average shares used to compute net income (loss) per share, diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">61,305,289</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">56,775,742</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">63,909,633</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">53,691,965</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">(1) Amount includes non-cash stock-based
compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>PROTAGONIST
THERAPEUTICS, INC.<BR>
<FONT STYLE="background-color: white">Stock-based Compensation</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><FONT STYLE="background-color: white"><B>(In
thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; text-indent: 0in">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,097</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,809</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">10,385</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">9,391</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 0in">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,847</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,534</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,911</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,536</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,944</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,343</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,296</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">15,927</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>PROTAGONIST THERAPEUTICS,
INC.<BR>
Selected Consolidated Balance Sheet Data<BR>
(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; text-indent: 0in">Cash, cash equivalents and marketable securities</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">595,444</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">341,617</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Receivable from collaboration partner</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Working capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">529,347</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">334,303</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Total assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">614,629</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">357,951</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(438,986</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(615,710</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in">Total stockholders' equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">541,324</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">336,677</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptgx-20240806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaGP+bOdzZR+CYkxtmBwbZl6Dywrkbaz3ScU6/zWIesM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ptgx="http://protagonist-inc.com/20240806" elementFormDefault="qualified" targetNamespace="http://protagonist-inc.com/20240806">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://protagonist-inc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20240806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20240806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ptgx-20240806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ptgx-20240806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://protagonist-inc.com/role/Cover" xlink:href="ptgx-20240806.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://protagonist-inc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2419327d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2419327d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ -L# 2(  A$! Q$!_\0
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M XS'QJ8]RY\9+!4)5O[/P$(RIQKYCC+.E@L/4KX>%2LK2K)>[/Z^T3_@K/\
ML.:U\-8_BG+\8!X;\/3ZC#H_V'QQX/\ &?@+Q/\ VU.K%-,;PKXNT#1]?%XT
MD,T;(U@JI+&\;.,,R?&G[0?P[^-/_!1SQ]\/M=^'W@2?P/\ "'PQIMW::)XW
M\>O8Z9<ZU#XEEL[V^UJUT:&XN-8N;*2'3]/?3(5BE81QS&=;%KLM%[3\8_'_
M /P1WU/]FB[\._&J\_9>U[X$K:2ZPWA#Q-9:/KVI-,+3RSK>D>&8H+OQW'XH
M2&2,F_TNV3Q.LTB*ETMRRNO\Z'_!O/\ #G]L[1?^"C_QC\4?LX>'/CU\)_\
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MND^(I)Y[6*^O?B;>^&-+T:[T.":%;S<^H:1%/;S0"?5]-MR=1'V+_P $E/\
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MP\"Z]H7AZZM?"NIV'C#PEHFJ:3%_:&D!#JSZ9_:DUUHTFJ6<_P ]^"OV=O\
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MP,<CG''3E"I*G)MU94HJ49XA**;E^L>'3\3J6:X*7#KQ]' O$4HXRIQ(J/\
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M^H[TX*!G'<Y/&/7V'^<4ZBNZRO>ROM>RO;U.&UDDM$MDMN^W35MZ6U"BBBF
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M;!I-\S2;;YKM*_-:W,WNY625V[V25[(QCH]H4,:6UNBM#+#F-0I$4S;I$!4
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03>MDW=I7O9-ZM+2^NY__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140193671159744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTAGONIST THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001377121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0505495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7707 Gateway Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94560-1160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">474-0170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTGX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MROW(HM;[B1>QV6ISHC4>)FS#/:Z_):Z"4:M0"43$XU3(F"B^'ED3>G?O=$U
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( !0Y!EF7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ %#D&6:K$(A8S 0
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M6N=6RKV'5[+E&''\GN4/4$L#!!0    ( !0Y!EDD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  4.09999!YDAD!  #/ P
M$P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=
M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'
M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-
MF<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*
M1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP
MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,
M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (
M !0Y!ED'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ %#D&65_C=<3N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %#D&69E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  4.099%:R[DF@$   B$0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %#D&69^@&_"Q
M @  X@P   T              ( !JPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    "  4.099EXJ[',     3 @  "P              @ &'#P  7W)E;',O
M+G)E;'-02P$"% ,4    "  4.099JL0B%C,!   B @  #P
M@ %P$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %#D&620>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ %#D&6660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2419327d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protagonist-inc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptgx-20240806.xsd</File>
    <File>ptgx-20240806_lab.xml</File>
    <File>ptgx-20240806_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2419327d1_8k.htm">tm2419327d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2419327d1_8k.htm": {
   "nsprefix": "ptgx",
   "nsuri": "http://protagonist-inc.com/20240806",
   "dts": {
    "schema": {
     "local": [
      "ptgx-20240806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ptgx-20240806_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgx-20240806_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2419327d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://protagonist-inc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2419327d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2419327d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-24-086088-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-086088-xbrl.zip
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M0N\?D@L:#T*DTOD!Q+!IQZ,4!0A'TUD?&D+M$XS+)(MPJKQ<BFU91_,L6M>
M@'9-2%K"H$"!W(&PJ #-3!'B%9A_$<R'X5)3^H&E9=6.2B4+$!336Q\F4N\%
MDOF6\X9K>,:!I<YNRO:8K>[/ KH@0.DQU[IKJ^0-4#S-0!<T3_*]?)[N>KM9
M$6YI7%OBB@W(G&;"+ ^"!<"4R8"2(:E#2NBEY_5= IK+AQC!YI@RMP38338I
M:&H"(L%J#*#AH"V>*?5"Q%R,3!RG"QJ3W<]D#[:KI7/+!&"S"84A"H@*NS,
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MO=H>S@:57I!I6[4"<Y"%ATO+6Q\L,D"N9V2(3TR*A=4-O^7L):$1O&2&Y%Z
M 4Q;J3&TX:%C-]C'3[4@UG%>QQJU*._]DFB9GU&F:=(^Q"A->) TC?4.+DKM
M$XE;EN4X_7?RW'DB;A=[P<-JV I)0QD>*C9[?<"H&"2"?)Q8E[C*&QK65\F,
M<G>O %ML'5X!KA4& 8'-4?L58'7U1(E<=[-DE!,,C C-8F>=;#%5]7&M+(PN
M;AMJ]7#QO18:'U]DF=TEO7UD%'Y H"UQU=.0.=W;9GD0/0Z8,GN]D*%"Y^EJ
MO,PPD=F'[UJ9LYG=M%--Y+H@B-XUW;2F:5WNN#=_XTDN]CQGF\V6EG=Y;,\-
M CI7O=QI4_>X511$[W<Y,TDHM:@I=HS%DJ5)E.0)7?\B3CYY@FVMLHE< 0$;
MU#2T%4&@ -HR.3@(D58ZAN"6$PDA$1U1O 0H$POQFX<'ZVS?)78%1;]A#0>L
M# *27GLF+")@'-4BD I!18Q?;!99MB7\3?!80CPA!)H'0&KI0\0),MD+E0KT
MR=:21%LQ/^Z/IZO[)$]M)Y=MB;,Y"3!7S4A&>1!L *9,%HHRQ![0\?2OJ[\A
M'>6X^Z_9/<<R>>QROUFQ%,@^956Y@J##HN; (@D"!=B72<,U0Z44*:V/[%0-
MLY;F&.6N +#:TEW?* RBTVV.6E_^1E][&O(O=M&C,$6 %Q+L,M=#O\VD.?S7
M-4$@T&&L=5)22I'6^G@AX3!EK?L7 6MOBX!USR)@'>(B8#UT$;#VM@C0NU4I
M0L2X=+-*DS4&DA-VJEU#T6'9Y,,B#0H5V!\X9E0AZ!#C.J-ED>),IN?GFV+_
ME^*#I96 SEE.RRZ;55)+FR@(1KJ<M=):JJ1S-3&2:M=<;.,D)[$R<YE03*,$
MIU5Z1-L5\?X09[0,-%^!TZ,/@Z%A)ELXJ3"=R[ */*2Z='TI73V \1M)TY\I
M>Z5+@C-&2:RNI=CN%'7KW3XQTV.[^= ,( X"IR$.@4=G9-#X248A'59>"?-"
MTC>6;FF.>?$N.;>-3(#.+3F S28QAB@@4NS. $(J,5)J/R]HJ^P1U2)+_>X0
MV$!([OAU[4[3QEO;5FU S'0:A-[A+G-^'-;&*LK3*Y8YD;\7D;R0+SC'I3>P
MO9#<]4N57:;-MREMVH 0ZC0(OC]9Q<A4,5@SY2UE#)^+I=::=3PE;JC<)XYI
M66SGCJDD >%A\]61088CK?7"PG*#T_3S-DLHR>")R%"Y9<%JL<E"0Q(0"S9?
M  N%%&FM%Q8N-H2OQ?3V$V>O^6.9GQ5L&Z!VRT:GY28C5FE K'3Y YC1(4C%
MZ)2Z?N#9'1**JRR+<$LM4L?8@&8-9EJZD("!S+5H24DDK[=<LQS=,_0U(RA_
M).BB_!FZ>B9X58^O7QJ)(OE"A%J5TQAS&T)=8N>_.@(:;OWV2$L9!$B]]N#?
M(:DBD YQ3,V-8)C7S^,*$XN<;,"W'?I#7!$TU+SFJ$\?!$T#39I,%6'-D^LB
M$,E(G]F,ZLGMX25>0^1X96PQ:"R,:XH@& %M0<OB^F\%^,F=MUVE2729,@Q?
M96EH'&?,:]LSDN4=! $1T'8%I<@KA*A0>NG_SY@^\>US'NUO.8L(D4]99=5H
MU7?];6"T6V;>U*0F38-" ^+L+7X! @]5H%H='VHSEL^+>?*A<9G-C45/RT<L
M#N#--L_D#"J,P5?!.X,<WUX8T #C)D-'1$#H#; )W7 H(E$1^@&I8%2+]G1^
MEAVR )+X\_Z./! NWSNX)[O\L]C14\<9QH!8UV=O@YMCGLSU!@8!X5O=0J=Z
M&:I7@%;R&;&R"O2[K 05M=A^O[R^Z4I\$IOU)O'7"F=$;/DO4$L#!!0    (
M !0Y!EGFT2HR70<  .-7   5    <'1G>"TR,#(T,#@P-E]P<F4N>&ULS9S?
M<]HX$,??;^;^!Q_W3 C0ZS5I<IV4A@[3M,F%M+V[EXZP!6@B2XPD!_CO3[(Q
MY8<E;UZ\R4-"S$K:[V=EV6M)OGBW2GGT1)5F4ERVNB>GK8B*6"9,S"Y;7\?M
MJ_%@-&I%VA"1$"X%O6P)V7KWUZ^_1/;GXK=V.QHRRI/SZ(.,VR,QE6^C+R2E
MY]%'*J@B1JJWT3?",W=$#AFG*AK(=,&IH?:+HN'SZ(^37I]$[3:@WF]4)%)]
MO1]MZYT;L]#GG<YRN3P1\HDLI7K4)[%,816.#3&9WM9VNCK=_!3%+S@3C^?N
MUX1H&EE>0I^O-+MLN78WS2[[)U+-.KW3TV[GG\\WXWA.4])FPG&+::LLY6JI
M*M<].SOKY-^6ID>6JXGB91O]3NG.MF;[+0O8[WBBV;G.W;N1,3%YV&N;B;P6
M[K]V:=9VA]K=7KO?/5GII%7"SPDJR>D]G4;NKXW>MM6%DH;,I&#:6&"QBUO'
MV70&TO9+ZW!>>J[H]+*U,+.5;:3WZO3-Z6O7Q.][1F:]L/U3,]>]6E%GK_F%
MHIH*DRN^L0?VBM"5L;V*)F5%KOUG.FB8<64V7:<;M5T_RU+;I/U86&[\*3WB
M,MYS@KMXR /%9=_.J6L:G\SD4R>AS-+O]=T'AZ.?H[#__,@;NIIHHTALRIHX
MF5">U__#VAR8=!KPJB3Q8&NL=FK?XM"GW=A=J3B2*J'*LB[K(BK>B]AQ-]U8
M=!9$V8K:\9SQ;;"G2J8^.AL2TN/H+BC;1#,TKVS[B?-AR,FL&N>!"9!G%P-H
MI1HLHA^HCA5;."XU8/<L@7Q[J'PKM#6,N3QW[NF,.7^=*^[B2]W!\+C@*0($
MW\<<*8)JD2)P)41&^#U=2%4#?M\2R/L5)N\J;4B8_\Z(,E3Q-83TD3$0]A^8
ML#T*D7@_*"(T<WP@P(^M@<1?H]YX>#0B(1_/*><NH2,"U,NK[('8_\3$[M?Y
M L!?/[GKN[VTP-GO% 'B?_-2\!^I18K '55,)O:2K@#LCXR!U,\PJ7L4HO*^
M%@F4]M84G/_@PSZ0AX1ZR'1,>.'1T![38=P5YE#D*#EGK4Q4[/]2HL#0=XRA
MR%'2T!J)#0,?9$KM.1,<5?S64.0H"6B=R(:97PO#S-K- 'S)TLG/!Z?[K(^M
MH(Q1DDZ?*!2VY9,&8=S$1HCOH264,4JN&1*'PGE@]2C"1R*AJT]T'0)]9 HE
MC9)C!N6AH+Y3+"5J/69Q_:!Q; N%C9)9A@6BT'X@JU%B5;$I*Z8&ZZ%[BT#9
MHZ25(+DH(1B)6*J%W'E</)"9/1_7 YD$A_2:@M!PH.2;SY".$I2K)+&X].;/
M#1.T&PI%I3EXC@@O  &9+P1[[WG8>W#L*'EHK<P7@KW_/.Q].':47+16)B;V
M@?UXJQ[DTC,#[36&(D?)16LD8@+/KS2WZD[))U:LD*JC?E0"BAXQ10V+1>WP
MQ44>TMM+2RAOQ'2U6APFYSNI#>'_L47=G62U/90Y8N(:$MKT \8B[NZAA6\I
MT8$)E"]*KEHIIVFD+L**$G_WW;>  D5)0*O$-,SS1KJYC[D4P>>QQU90KBB9
MI$]4TP.O6T^LO:?^SM?@%6PHP^JAC(8Q?E?,6 \&,DTSL7E&XYD5\YA"\:*D
M?T%Y#:,>2\YB9IB8?;9WB(H17LVYR@X*&279\PMKF/"=HB[2U-YVY^NXW(8#
M=3N=^D;>D#V4.$JN5R\4E_Q(ZXRJY_*O* 6- DK:!Q7=]#A#X\P.>^MN;_+@
M=LQX1IDC*RAKE)3/)ZIAME_D@R)NY]YXG4XD]V\/J32$$D9)\ +2&H:\YT<U
MW@,3*%B4S*Y2#M*8<+V*YT3,J'_U0K4E%#!*IA<2AS;VSD!C[^R98R]*QN<3
MA<2V6!MNSZC;"6<SXM])%BP WF>#23P@M>G]>_F6'[>G6Z6Y'T/[H1J[QQ0*
M'&>+9$A>TZBSA!F:%"X-F2 BMBG5=E^;)SNO+P4- ,X>2J!HE,?[WRGGGX1<
MBC$E6@J:%+?ZH2?\WB+0*"#.(=;(10G!-\DS2TGE"T&5YQSPF$*1(\X=>N3A
MK+TL%C5OKSW%RSM"Q'TEH. 1)Q'#8I'6IQGJ?&9/] ,Q9.-AB+^O!)0_XH1B
M6"S:^GDUL!>>F0S/F1\80FDC+H6ME(8">9P2SM]GF@FJ@V/+@2$4,N*:UTII
M*)"O4ZIF=E#[J.32S#=[.T.P/06@T!%7M@:EXL!?_=Q'7NQ_"Y*OL :_G0 1
MNU<DUFLWXM@MI"BNY"(ARD,]9 _ECKJQTB^T8?*W9D[5[OU3[LS(YFVA10_U
MI:!10$E7H:)QKJT[._F#E]8].RAOQ,2T2AC.GJELPED\Y)($[\OWS*!\$;/0
M"EDH>-\3\:BRA8G7=TK&E+KI$[T]VP )$; ":$@0\]-GH<!Y7"#3U&TFDO'C
M>&Y%Z]O,Y.\RM?X%'QH$RT%#@[F)$R <Z2Y(_]SH19/WZWLZI<HM4WB@*_/>
M-O08OBD"%(?&!_6-0F ,%6&ZZ!SINK$'W-MJBV_<+_=&5GOD?U!+ P04
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M=/6+<]HV'XY=B:3XKX<1OW_('FJ5_P%02P,$%     @ %#D&69@CUG+R(0
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MFHT U"P,E,HF#I3!9X/4FO# !R<Y"G(Z@0>Z#V0H_XEW6=@ #&AJ#\6TOA.
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M\0\<Q^K#N7EP#Z@LE:DK TTNR]$DLUOLYC1"S7C0CX /*Q HQ=Q-##GB2$Q
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M01_8I>;YZ4DE;#VNO^;[DXFQ]O[3]=E?>/ON_9?6U\N3_P=02P$"% ,4
M"  4.099+1KH;2\#  #X"P  $0              @ $     <'1G>"TR,#(T
M,#@P-BYX<V102P$"% ,4    "  4.099E8SM0_T*  " A@  %0
M    @ %> P  <'1G>"TR,#(T,#@P-E]L86(N>&UL4$L! A0#%     @ %#D&
M6>;1*C)=!P  XU<  !4              ( !C@X  '!T9W@M,C R-# X,#9?
M<')E+GAM;%!+ 0(4 Q0    ( !0Y!EG:5O3*11,  &-L   2
M  "  1X6  !T;3(T,3DS,C=D,5\X:RYH=&U02P$"% ,4    "  4.099F"/6
M<O(A  #(/@$ %@              @ &3*0  =&TR-#$Y,S(W9#%?97@Y.2TQ
:+FAT;5!+!08     !0 % $D!  "Y2P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2419327d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptgx-20240806.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-06" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-06" id="Fact000004">0001377121</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-06" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-06" id="Fact000010">2024-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-06" id="Fact000011">PROTAGONIST THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-06" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-06" id="Fact000013">001-37852</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-06" id="Fact000014">98-0505495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-06" id="Fact000015">7707 Gateway Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-06" id="Fact000016">Suite 140</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-06" id="Fact000017">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-06" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-06" id="Fact000019">94560-1160</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-06" id="Fact000020">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-06" id="Fact000021">474-0170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-06" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-06" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-06" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-06" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-06" id="Fact000026">Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-06" id="Fact000027">PTGX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-06" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-06" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
